Related Experiment Videos
Work in progress: 252Cf neutron brachytherapy for hemispheric malignant glioma.
Radiology
|October 1, 1982
Summary
Californium-252 neutron brachytherapy for malignant glioma is feasible and safe. Combining it with photon beam therapy showed patient improvement and reduced tumor size.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Malignant glioma presents a significant therapeutic challenge.
- Advanced treatment modalities are continuously explored for improved patient outcomes.
Purpose of the Study:
- To evaluate the feasibility and tolerability of Californium-252 (252Cf) neutron brachytherapy for hemispheric malignant glioma.
- To assess the combination of 252Cf neutron brachytherapy with external whole brain photon beam therapy.
Main Methods:
- Ten patients with hemispheric malignant glioma underwent 252Cf neutron brachytherapy.
- This was combined with external whole brain photon beam therapy (6,000 rad over 5-7 weeks).
Main Results:
- The combined treatment protocol was well-tolerated by all ten patients.
- Observed improvements in patient performance status.
- Computed tomographic scans indicated a decrease in tumor size.
Conclusions:
- 252Cf neutron brachytherapy is a readily achievable and safe procedure for malignant glioma.
- The combination of 252Cf neutron brachytherapy and photon beam therapy shows promise for managing malignant glioma.